Immunomodulating and Immunosuppressive Therapy for Virus-Negative Immune-Mediated Myocarditis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39062138/
Myocarditis is an inflammatory disease of the myocardium caused by infectious and noninfectious agents. Clinical manifestations range from mildly symptomatic forms to acute heart failure, cardiogenic shock, life-threatening arrhythmias and...
Myocarditis, an inflammatory heart condition, presents varying symptoms. Immunosuppressive therapy is debated, though effective in specific cases. Diagnosis via endomyocardial biopsy guides tailored treatment strategies.
Share
Update: factors influencing heart rate variability-a narrative review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39165281/
In order to improve the quality of HRV studies and to ensure accurate interpretation, it is recommended that confounders be taken into account in future diagnostic measurements or measurements in...
This narrative review highlights factors influencing heart rate variability (HRV), categorizing them as non-influenceable physiological factors, diseases, lifestyle choices, and external elements, stressing the importance of considering these confounders in HRV interpretation.
Share
Heart Failure: a Punch from the Gut
Source : https://pubmed.ncbi.nlm.nih.gov/38300390/
A growing field of research is focused on the effects of a "leaky gut" in the development of disease across organ systems. The leaky gut hypothesis centers on intestinal epithelial...
Targeting gut composition may significantly improve heart failure (HF) outcomes by addressing gut dysbiosis and epithelial barrier dysfunction, highlighting a crucial therapeutic avenue.
Share
Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial Infarction
Source : https://pubmed.ncbi.nlm.nih.gov/38588929/
In patients with AMI, the severity of left ventricular dysfunction and the presence of congestion was associated with worse outcomes. Empagliflozin reduced first and total HF hospitalizations across the range...
Empagliflozin reduced HF hospitalizations post-AMI, regardless of LVEF or congestion, with consistent safety. Severity of LVEF dysfunction and congestion correlated with worse outcomes.
Share
Where Are We With Treatment and Prevention of Heart Failure in Patients Post-Myocardial Infarction
Source : https://pubmed.ncbi.nlm.nih.gov/38878010/
As a result of the widespread use of reperfusion therapies and secondary prevention over the last 30 years, there has been a dramatic reduction in the risk of mortality and...
Despite advances in reperfusion and secondary prevention, chronic heart failure (HF) remains common post-myocardial infarction (MI). Neurohormonal inhibition and emerging therapies aim to mitigate HF risk and myocardial damage.
Share